SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Fibrocell Science, Inc. (NASDAQ GS: FCSC)

BALA CYNWYD, October 17, 2019 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Fibrocell Science, Inc. (“Fibrocell” or “the Company”) (NASDAQ GS:FCSC) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Castle Creek Pharmaceutical Holdings, Inc. (“Castle Creek”). Under the terms of the agreement, Fibrocell shareholders will receive only $3.00 for each share of Fibrocell common stock owned.

The investigation concerns whether the Fibrocell Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Castle Creek is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Fibrocell shareholders. For example, the stock traded at over $20.00 a share just two years ago.

If you own shares of Fibrocell stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.